Cargando…
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778912/ https://www.ncbi.nlm.nih.gov/pubmed/35062789 http://dx.doi.org/10.3390/vaccines10010128 |
_version_ | 1784637445240782848 |
---|---|
author | Wongso, Hendris Mahendra, Isa Arnafia, Wyanda Idar, Idar Yusuf, Muhammad Achmad, Arifudin Holik, Holis A. Kurniawan, Ahmad Halimah, Iim Sriyani, Maula E. Wibawa, Teguh H. A. Febrian, Muhamad B. Setiadi, Yanuar Widyasari, Eva M. Daruwati, Isti Kusumaningrum, Crhisterra E. Subroto, Toto |
author_facet | Wongso, Hendris Mahendra, Isa Arnafia, Wyanda Idar, Idar Yusuf, Muhammad Achmad, Arifudin Holik, Holis A. Kurniawan, Ahmad Halimah, Iim Sriyani, Maula E. Wibawa, Teguh H. A. Febrian, Muhamad B. Setiadi, Yanuar Widyasari, Eva M. Daruwati, Isti Kusumaningrum, Crhisterra E. Subroto, Toto |
author_sort | Wongso, Hendris |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19. |
format | Online Article Text |
id | pubmed-8778912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87789122022-01-22 Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 Wongso, Hendris Mahendra, Isa Arnafia, Wyanda Idar, Idar Yusuf, Muhammad Achmad, Arifudin Holik, Holis A. Kurniawan, Ahmad Halimah, Iim Sriyani, Maula E. Wibawa, Teguh H. A. Febrian, Muhamad B. Setiadi, Yanuar Widyasari, Eva M. Daruwati, Isti Kusumaningrum, Crhisterra E. Subroto, Toto Vaccines (Basel) Article The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19. MDPI 2022-01-17 /pmc/articles/PMC8778912/ /pubmed/35062789 http://dx.doi.org/10.3390/vaccines10010128 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wongso, Hendris Mahendra, Isa Arnafia, Wyanda Idar, Idar Yusuf, Muhammad Achmad, Arifudin Holik, Holis A. Kurniawan, Ahmad Halimah, Iim Sriyani, Maula E. Wibawa, Teguh H. A. Febrian, Muhamad B. Setiadi, Yanuar Widyasari, Eva M. Daruwati, Isti Kusumaningrum, Crhisterra E. Subroto, Toto Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title | Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title_full | Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title_fullStr | Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title_full_unstemmed | Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title_short | Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 |
title_sort | preclinical evaluation of chicken egg yolk antibody (igy) anti-rbd spike sars-cov-2—a candidate for passive immunization against covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778912/ https://www.ncbi.nlm.nih.gov/pubmed/35062789 http://dx.doi.org/10.3390/vaccines10010128 |
work_keys_str_mv | AT wongsohendris preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT mahendraisa preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT arnafiawyanda preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT idaridar preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT yusufmuhammad preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT achmadarifudin preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT holikholisa preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT kurniawanahmad preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT halimahiim preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT sriyanimaulae preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT wibawateguhha preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT febrianmuhamadb preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT setiadiyanuar preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT widyasarievam preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT daruwatiisti preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT kusumaningrumcrhisterrae preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 AT subrotototo preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19 |